SCHEMBL4300784

SCHEMBL4300784

COc1cc(C(=O)NC2CN(C)C2)ccc1Nc1ncc2c(n1)N(C1CCCCC1)CC1(CC1)C(=O)N2C

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK1 P53350 17/20 0.73
BRD4 O60885 6/20 0.73
BRDT Q58F21 6/20 0.73
RAD52 P43351 1/20 0.68
PLK3 Q9H4B4 3/20 0.61
PRKD3 O94806 1/20 0.61
MAP4K4 O95819 1/20 0.61
PRKCG P05129 1/20 0.61
CLK2 P49760 1/20 0.61
RPS6KA3 P51812 1/20 0.61
NEK4 P51957 1/20 0.61
PTK2 Q05397 1/20 0.61
CAMK2G Q13555 1/20 0.61
CAMK2D Q13557 1/20 0.61
SRPK1 Q96SB4 1/20 0.61
PRKD2 Q9BZL6 1/20 0.61
CSNK1G1 Q9HCP0 1/20 0.61
CSNK1G3 Q9Y6M4 1/20 0.61
ALK Q9UM73 1/20 0.61
PLK2 Q9NYY3 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4109042 0.99 PLK1 (0.74) PLK1BRD4BRDTRAD52PLK3
SCHEMBL23025803 0.96 PLK1 (0.77) PLK1BRD4BRDTRAD52PLK3
SCHEMBL4297721 0.95 PLK1 (0.75) PLK1BRD4BRDTRAD52PLK3
SCHEMBL4297750 0.95 PLK1 (0.75) PLK1BRD4BRDTRAD52PLK3
SCHEMBL4301929 0.95 PLK1 (0.75) PLK1BRD4BRDTRAD52PLK3
SCHEMBL2397141 0.95 PLK1 (0.78) PLK1BRD4BRDTRAD52PLK3
SCHEMBL4300264 0.94 PLK1 (0.76) PLK1BRD4BRDTRAD52PLK3
SCHEMBL4300259 0.94 PLK1 (0.76) PLK1BRD4BRDTRAD52PLK3
SCHEMBL4108783 0.94 PLK1 (0.76) PLK1BRD4BRDTRAD52PLK3
SCHEMBL4097677 0.94 PLK1 (0.80) PLK1BRD4BRDTRAD52PLK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090291938-A1 POLO-LIKE KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-26 US claimed
US-20090291938-A1 POLO-LIKE KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-26 US disclosed
US-20090291938-A1 POLO-LIKE KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-26 US disclosed
US-20090291938-A1 POLO-LIKE KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-26 US disclosed
WO-2009067547-A1 POLO-LIKE KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291938-A1 POLO-LIKE KINASE INHIBITORS PLK1, PLK2, POLK PLK1 1/4885BRD4 1323/4885BRDT 579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.